LAV Biosciences Fund V, L.P. reported conversion involving 1,953,774 derivative units of ADARx Pharmaceuticals, Inc. at $0.00 for $0 on Sep 28, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
10% owner
10%
Filed Sep 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
1,953,774Series B Preferred Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Sep 28, 2026Conversion
Filed
Sep 29, 2026, 9:38 PM ET2-day reporting delay
Accession
0001231919-26-001406Code C · Transaction 231460
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 28, 2026Conversion601,161$0.00$0Trade 231461
Sep 28, 2026Conversion180,288$0.00$0Trade 231462
Sep 28, 2026Conversion360,577$0.00$0Trade 231463
Sep 28, 2026Conversion10,438,412$0.00$0Trade 231459
Sep 28, 2026Conversion8,908,775——Trade 231453
Sep 28, 2026Conversion1,667,469——Trade 231454
Sep 28, 2026Conversion513,067——Trade 231455
Sep 28, 2026Conversion153,868——Trade 231456
Sep 28, 2026Conversion307,738——Trade 231457
Sep 28, 2026Conversion307,738——Trade 231458
11 transaction rows in this filing. Joint filers share the same rows.

ADRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −13%30d −10%90d180d1y

Footnotes in full

F1: Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 reverse stock split basis into shares of Common Stock upon the closing of the Issuer's initial public offering on September 28, 2026, without payment of further consideration. The Preferred Stock has no expiration date. F2: LAV GP V, L.P. is the general partner of LAV Biosciences Fund V, L.P. ("LAV Biosciences"). LAV Corporate V GP, Ltd. is the general partner of LAV GP V, L.P. Dr. Yi Shi is the managing partner of LAV Corporate V GP, Ltd. By virtue of these relationships, LAV GP V, L.P., LAV Corporate V GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Biosciences. F3: Shares are held by LAV Fund VI, L.P. ("LAV Fund VI"). LAV GP VI, L.P. ("LAV GP VI") is the general partner of LAV Fund VI and LAV Corporate VI GP, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI, L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP, Ltd. By virtue of these relationships, LAV GP VI, L.P., LAV Corporate VI GP, Ltd. and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI, L.P. F4: Shares are held by LAV Fund VI Opportunities, L.P. ("LAV Fund VI Opportunities"). LAV GP VI Opportunities, L.P. ("LAV GP VI Opportunities") is the general partner of LAV Fund VI Opportunities, L.P. and LAV Corporate VI GP Opportunities, Ltd. ("LAV Corporate VI GP") is the general partner of LAV GP VI Opportunities, L.P. Dr. Yi Shi is the managing partner of LAV Corporate VI GP Opportunities, Ltd. By virtue of these relationships, LAV GP VI Opportunities, L.P., LAV Corporate VI GP Opportunities, Ltd., and Dr. Yi Shi may be deemed to have voting and investment power of the shares held by LAV Fund VI Opportunities, L.P.